
Amanda J Cork

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8237951/publications.pdf Version: 2024-02-01



AMANDALCORK

#	Article	IF	CITATIONS
1	Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection. MBio, 2022, 13, e0351721.	4.1	11
2	Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria. Antibiotics, 2022, 11, 449.	3.7	3
3	A multivalent T-antigen-based vaccine for Group A Streptococcus. Scientific Reports, 2021, 11, 4353.	3.3	20
4	Streptolysins are the primary inflammasome activators in macrophages during <i>Streptococcus pyogenes</i> infection. Immunology and Cell Biology, 2021, 99, 1040-1052.	2.3	12
5	Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes. Nature Communications, 2020, 11, 5018.	12.8	35
6	Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis. Science Translational Medicine, 2020, 12, .	12.4	36
7	Vaccine-Induced Th1-Type Response Protects against Invasive Group A <i>Streptococcus</i> Infection in the Absence of Opsonizing Antibodies. MBio, 2020, 11, .	4.1	33
8	Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nature Genetics, 2019, 51, 1035-1043.	21.4	120
9	An Experimental Group A <i>Streptococcus</i> Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model. MBio, 2019, 10, .	4.1	57
10	Endopeptidase PepO Regulates the SpeB Cysteine Protease and Is Essential for the Virulence of Invasive M1T1 Streptococcus pyogenes. Journal of Bacteriology, 2018, 200, .	2.2	18
11	Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance. MBio, 2018, 9, .	4.1	56
12	Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models. MBio, 2016, 7, .	4.1	51
13	Stability of the Octameric Structure Affects Plasminogen-Binding Capacity of Streptococcal Enolase. PLoS ONE, 2015, 10, e0121764.	2.5	14
14	Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone. FASEB Journal, 2012, 26, 4675-4684.	0.5	48
15	Conserved anchorless surface proteins as group A streptococcal vaccine candidates. Journal of Molecular Medicine, 2012, 90, 1197-1207.	3.9	49
16	Parameters Governing Invasive Disease Propensity of Non-M1 Serotype Group A Streptococci. Journal of Innate Immunity, 2010, 2, 596-606.	3.8	36
17	Defining the Structural Basis of Human Plasminogen Binding by Streptococcal Surface Enolase. Journal of Biological Chemistry, 2009, 284, 17129-17137.	3.4	61
18	M proteinâ€mediated plasminogen binding is essential for the virulence of an invasive <i>Streptococcus pyogenes</i> isolate. FASEB Journal, 2008, 22, 2715-2722.	0.5	72

#	Article	IF	CITATIONS
19	Allelic variants of streptokinase from <i>Streptococcus pyogenes</i> display functional differences in plasminogen activation. FASEB Journal, 2008, 22, 3146-3153.	0.5	55
20	Trigger for group A streptococcal M1T1 invasive disease. FASEB Journal, 2006, 20, 1745-1747.	0.5	140